The histochemical antibody for Vesicular Monoamine Trnasporter 2 (VMAT2) is generated in a rabbit from a synthetic peptide corresponding to rat VMAT2 496-515 coupled to carrier protein. The antiserum is provided as l00 µL of lyophilized whole serum.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Rabbit
Species Reactivity:
Rat
Expected Species:
100% sequence homology with rat, 85% with mouse and 93% with human
Immunogen:
Synthetic peptide corresponding to rat VMAT2 496-515 coupled to carrier protein.
Applications:
Immunohistochemistry, Immunocytochemistry, Western Blot
The VMAT2 antiserum was quality control tested using standard immunohistochemical methods in rat brain and adrenal medulla using biotin/avidin-HRP techniques. Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with an excess of rat VMAT2 peptide residues 496-515. Western blot analysis of immunoprecipitated rat brain homogenates demonstrates a dense immunoreactive band of approximately 55 kD and a minor band of approximately 75 kD.
The histochemical antibody for Vesicular Monoamine Transporter 1 (VMAT1) is generated in a rabbit from a synthetic peptide corresponding to rat VMAT1 502-521 coupled to carrier protein. The antiserum is provided as l00 µL of lyophilized whole serum.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Rabbit
Species Reactivity:
Rat
Expected Species:
100% sequence homology with rat, 90% with mouse and human
Immunogen:
Synthetic peptide corresponding to rat VMAT1 502-521 coupled to carrier protein.
Applications:
Immunohistochemistry, Immunocytochemistry, Western Blot
The VMAT1 antiserum was quality control tested using standard immunohistochemical methods in rat adrenal medulla using biotin/avidin-HRP techniques; the antiserum shows no reactivity in rat CNS. Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with an excess of rat VMAT1 peptide residues 502-521. Western blot analysis of immunoprecipitated rat adrenal homogenates demonstrates a dense immunoreactive band of approximately 55 kD and a minor band of approximately 75 kD.
The antibody has a proven strong fluorescent staining at a 1/200-1/400 dilution and a strong Biotin-Streptavidin/HRP staining at a 1/4000-1/6000 dilution in rat amygdala, cortex, and suprachiasmatic nucleus. The specificity of the antiserum was examined by soluble pre-adsorption with the peptides in question at a final concentration of 10-5 M. VIP immunolabeling was completely abolished by pre-adsorption with VIP. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: Secretin, gastric inhibitory polypeptide, somatostatin, glucagon, insulin, ACTH, gastrin 34, FMRF-amide, rat GHRF, human GHRF, peptide histidine isoleucine 27, rat pancreatic polypeptide, motilin, peptide YY, substance P, neuropeptide Y, and CGRP. The histochemical antibody for VIP is generated in a rabbit against porcine VIP conjugated to bovine thyroglobulin with carbodiimide. The antibody is provided as 100 µL of lyophilized whole serum, and 0.09% sodium azide.
The ImmunoStar VIAAT antiserum was quality control tested using standard immunohistochemical methods in rat brain and spinal cord using biotin/avidin-HRP techniques.Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with an excess of rat VIAAT peptide residues 511-525. Western blot analysis of immunoprecipitated rat brain homogenates demonstrates a dense immunoreactive band of approximately 57 kD and a minor band of approximately 36 kD.
The antibody produces strong labeling of VAChT at dilutions of 1/200 - 1/400 using indirect immunofluorescence and at dilutions of 1/3,000 - 1/5,000 using biotin-streptavidin/HRP technique in rat basal forebrain.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Goat
Species Reactivity:
Human, Mouse, Rat
Immunogen:
Rat VAChT 511-530
Applications:
Electron Microscopy; Immunocytochemistry; Immunofluorescence; Immunohistochemistry.
Solute carrier family 18, member 3;solute carrier family 18 (vesicular monoamine) member 3; solute carrier family 18 (vesicular acetylcholine), member 3;rVAT; VACht
Additional Info:
The VAT Antibody produces strong labeling of VAChT at a dilution of 1/3,000 - 1/5,000 using biotin-streptavidin/HRP technique in rat basal forebrain.
Gene Symbol:
Slc18a3,60422
NCBI Gene Aliases:
Solute carrier family 18, member 3; member 3;rVAT; VACht
The antibody has a proven strong fluorescent staining at a 1/400 - 1/800 dilution and a proven strong biotin-streptavidin/HRP staining at a 1/2000 - 1/4000 dilution in rat hypothalamus. Staining is completely eliminated by pretreatment of the diluted antibody with 10 µg/mL of arginine vasopressin. Pre-adsorption with as much as 100 µg/mL of oxytocin had no effect on immunolabeling.
The Tyrosine Hydroxylase antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat catecholamine neuron systems using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions for these methods are provided below. This antibody does not cross react with dihydropterdine reductase, dopamine-B-hydroxylase, phenylethanolamine-N-methyltransferase, phenylalanine hydroxylase or tryptophan hydroxylase using Western blot methods.
The Substance P antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat substantia nigra and spinal cord using biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500-1/1000 in PBS/0.3% Triton X-100 - Cy3 Fluorchrome and 1/6000-1/8000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. The specificity of the antiserum for Substance P was demonstrated using soluble pre-adsorption with the peptides in question at a final concentration of 10 µg of peptide per mL of diluted antiserum. Substance P immunolabeling was completely abolished by pre-adsorption with Substance P. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: neurokinin A, neurokinin B, somatostatin and neuropeptide K.
The antibody has a proven strong immunofluorescent staining at a 1/200-1/400 dilution, and a 4+ Biotin-Streptavidin/HRP staining at a 1/500-1/1000 dilution, in rat adrenal medulla and rat stomach.
The antibody has a proven strong indirect immunofluorescent staining at a 1/400-1/800 dilution and strong Biotin-Streptavidin/HRP staining at a 1/1000-1/2000 dilution in rat hypothalamus (median eminence). The specificity of the antiserum was examined by soluble pre-adsorption with the peptides in question at a final concentration of 106M. Somatostatin immunolabeling was completely abolished by pre-adsorption with somatostatin, somatostatin 25, and somatostatin 28. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: substance P, amylin, glucagon, insulin, neuropeptide Y, and VIP.
The antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat thalamus, cortex, and hippocampus. The antiserum has been characterized as specific to parvalbumin; please see reference listed below. Recommended primary dilutions are 1/400 - 1/800 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/5,000 - 1/8,000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique.
The Oxytocin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200 - 1/400 in PBS/0.3% Triton X-100 - FITC and 1/4,000 - 1/8,000 in PBS/0.3% Triton X-100 - Bn/Av-HRP. Staining is completely eliminated by pretreatment of 1 mL of the diluted antibody with 5 µg of Oxytocin. Pretreatment of 1 mL of the diluted antibody with as much as 100 µg of vasopressin does not diminish staining.
Pre-adsorption of Mu Opioid Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/ml Mu Opioid Receptor peptide immunogen following the instructions below provides complete blockage of Mu Opioid Receptor immunolabeling.
The Mu Opioid Receptor antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat caudate putamen and spinal cord (dorsal horn) using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/6000 - 1/10000 in PBS/0.3% Triton X-100 - Biotin/avidin-HRP Technique. Preadsorption with MOR peptide (384-398) at 10 µg/ml completely eliminates labeling. The specificity of the antiserum was determined by immunolabeling of transfected cells, Western Blot analysis and immunoisolation studies.
The peptide control for nNOS (N-terminal) is intended for the immuno-adsorption of nNOS (N-terminal) antiserum, catalog number 24431. Pre-adsorption of nNOS (N-terminal) antiserum, diluted according to the antibody specification sheet, with 5ug/ml nNOS (N-terminal) peptide immunogen following the instructions below provides complete blockage of nNOS (N-terminal) immunolabeling. The peptide is provided as 25ug of lyophilized human nNOS (N-terminal), and approximately 0.09% sodium azide, sequence 134-148. Please read the instructions carefully.
The ImmunoStar N-terminal neuronal nitric oxide synthase antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus, striatum, cortex and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/1,000 - 1/2,000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP. By Western blot analysis of brain homogenates the antibody specifically labels a band of approximately 155 kD. Immunolabeling is completely abolished by pre-adsorption with synthetic human nNOS (134-148) at 5 µg per mL of diluted antibody. No cross reactivity with other forms of NOS was observed.
The peptide control for nNOS (C-terminal) is intended for the immuno-adsorption of nNOS (C-terminal) antiserum, catalog number 24287. Pre-adsorption of nNOS (C-terminal) antiserum, diluted according to the antibody specification sheet, with 5 µg/ml nNOS peptide immunogen following the instructions below provides complete blockage of nNOS (C-terminal) immunolabeling. The peptide is provided as 25 µg of lyophilized human nNOS, sequence 1419-1433. Please read the instructions carefully before beginning the procedure.
The neuronal nitric oxide synthase C-terminal antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus, striatum, cortex and spinal cord using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/1,000 - 1/1,500 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/8,000 - 1/12,000 in PBS/0.3% Triton X-100 - Bn/Av-HRP Technique. By Western blot analysis of brain homogenates the antibody specifically labels a band of approximately 155 kD. Immuno-labeling is completely abolished by pre-adsorption with synthetic human nNOS (1419-1433) at 5 µg per mL of diluted antibody. No cross reactivity with other forms of NOS were observed. The nNOS antiserum has been used successfully in human, rat, mouse, guinea pig, cat, and monkey tissue. Detection of nNOS from other species will depend upon sequence homology.
The histochemical antibody for Neurokinin 3 Receptor is generated in a rabbit from a synthetic peptide corresponding to rat NK3R 438-452 coupled to carrier protein. The antiserum is provided as l00 µL of affinity purified liquid.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Liquid
Host Animal:
Rabbit
Species Reactivity:
Rat
Expected Species:
100% sequence homology with rat, human, mouse, dog and gerbil
Immunogen:
Synthetic peptide corresponding to rat NK3R 438-452 coupled to carrier protein.
The NK3R antiserum was quality control tested using standard immunohistochemical methods in rat hypothalamus using biotin/avidin-HRP techniques.Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with 25 mg of rat NK3R peptide residues 438-452. Western blot analysis of crude rat brain homogenate demonstrates two immunoreactive bands of approximately 80 and 115 kD.
The peptide control for Neurokinin 1 Receptor is intended for the immuno-adsorption of Neurokinin 1 Receptor antiserum, catalog number 20060. Pre-adsorption of Neurokinin 1 Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/mL NK1R peptide immunogen following the instructions below provides complete blockage of Neurokinin 1 Receptor immunolabeling.
The peptide control for Neurokinin 1 Receptor is intended for the immuno-adsorption of Neurokinin 1 Receptor antiserum, catalog number 20060. Pre-adsorption of Neurokinin 1 Receptor antiserum, diluted according to the antibody specification sheet, with 10 µg/mL NK1R peptide immunogen following the instructions below provides complete blockage of Neurokinin 1 Receptor immunolabeling. The peptide is provided as 100 µL of 50 mg of synthetic peptide corresponding to rat NK1R 393-407.
The histochemical antibody for Neurokinin 1 Receptor is generated in a rabbit from a synthetic peptide corresponding to rat NK1R 393-407 coupled to carrier protein. The antiserum is provided as l00 µL of lyophilized whole serum.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Rabbit
Species Reactivity:
Rat
Expected Species:
100% sequence homology with rat and gerbil, 93% with mouse, 78% with human
Immunogen:
Synthetic peptide corresponding to rat NK1R 393-407 coupled to carrier protein.
The NK1R antiserum was quality control tested using standard immunohistochemical methods in rat brain using biotin/avidin-HRP techniques. Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with 10 mg of rat NK1R peptide residues 393-407. Western blot analysis demonstrates two immunoreactive bands of approximately 70 and 110 kD.
The Neurotensin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat amygdala using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200-1/400 in PBS/0.3% Triton x-100 - Cy3 Technique and 1/4000-1/8000 in PBS/0.3% Triton x-100 - Bn/Av-HRP Technique. Staining is completely eliminated by pretreatment with 10 µg of Neurotensin per 1 mL of diluted antibody.
The Neuropeptide Y Y1 Receptor was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat cortex, arcuate and hippocampus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS - Bn/Av-HRP detection.
The antibody was characterized by immunohistochemistry and Western blot. Western blot showed one immunoreactive band of 40 kD and a single high molecular weight band, presumably a precursor molecule. Preincubation of the antibody with an excess of the synthetic peptide blocked staining. Immunohistochemical staining of rat brain correlates well with Northern analysis, in situ hybridization and receptor autoradiography. BlastP database sequence homology searches confirmed that this sequence is unique to rat, mouse and human NPY Y1 receptors.
Neuropeptide Y (NPY) is a member of a regulatory peptide family and has a marked sequence homology with pancreatic polypeptide (PP) and peptide YY (PYY), which are other members of the family. In the rat central nervous system, immunohistochemistry has found NPY-like cell bodies in the cortex, caudate-putamen, hypothalamus (arcuate nucleus), hippocampus, anterior olfactory bulb, nucleus accumbens, amygdaloid complex and periaqueductal grey. NPY-like fibers and terminals are detected in high numbers in the bed nucleus of the stria terminalis, the peri- and paraventricular regions of the hypothalamus and thalamus and in discrete hypothalamic nuclei, particularly the suprachiasmatic nucleus. It has been used to detect NPY in a wide range of species including rat, mouse, human (1-7), fish, cat, bird, guinea pig, zebrafish, squirrels, frog, and newt.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.